Revenue
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
UNITED THERAPEUTICS Corp (UTHR)
Price$487.61Cached quote
Net income
2008
2009
2010
2015
2016
2017
2018
2019
2021
2022
2023
2024
2025
Free cash flow
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B | $1.48B | $1.45B | $1.63B | $1.73B | $1.60B | $1.47B | $1.29B | $1.12B | $916.1M | $743.2M | $592.9M | $358.9M | $281.5M |
| Gross profit | $2.80B | $2.57B | $2.07B | $1.78B | $1.56B | $1.38B | $1.33B | $1.43B | $1.62B | $1.53B | $1.40B | $1.15B | $975.8M | $786.8M | $652.2M | $524.0M | $316.8M | $254.5M |
| Gross margin | 87.92% | 89.24% | 88.94% | 92.17% | 92.73% | 92.71% | 91.88% | 87.79% | 93.87% | 95.45% | 95.29% | 89.53% | 87.36% | 85.89% | 87.76% | 88.38% | 88.27% | 90.42% |
| Research & development | $550.0M | $481.0M | $408.0M | $322.9M | $540.1M | $357.7M | $1.18B | $357.9M | $264.6M | $147.6M | $245.1M | $242.5M | $299.3M | $173.4M | $180.0M | $165.3M | $120.4M | $239.2M |
| Operating expenses | $1.69B | $1.50B | $1.14B | $956.6M | $1.13B | $889.7M | $1.64B | $822.4M | $910.4M | $537.1M | $766.8M | $749.7M | $824.5M | $494.4M | $425.4M | $421.6M | $333.1M | $363.6M |
| Operating income | $1.49B | $1.38B | $1.18B | $979.7M | $555.9M | $593.6M | −$187.6M | $805.4M | $814.9M | $1.06B | $699.0M | $538.8M | $292.5M | $421.6M | $317.8M | $171.3M | $25.8M | −$82.1M |
| Operating margin | 46.89% | 47.86% | 50.91% | 50.60% | 32.98% | 40.02% | −12.95% | 49.48% | 47.23% | 66.41% | 47.69% | 41.82% | 26.19% | 46.03% | 42.76% | 28.89% | 7.18% | −29.15% |
| EBITDA | $1.58B | $1.45B | $1.24B | $1.03B | $605.8M | $643.5M | −$141.7M | $841.3M | $845.9M | $1.09B | $731.9M | $571.0M | $323.8M | $448.8M | $338.3M | $189.2M | $37.2M | −$77.5M |
| EBITDA margin | 49.58% | 50.38% | 53.19% | 53.25% | 35.94% | 43.38% | −9.78% | 51.68% | 49.03% | 68.38% | 49.93% | 44.32% | 28.99% | 48.99% | 45.52% | 31.92% | 10.35% | −27.54% |
| Net income | $1.33B | $1.20B | $984.8M | $727.3M | $475.8M | — | −$104.5M | $589.2M | $417.9M | $713.7M | $651.6M | — | — | — | — | $105.9M | $19.5M | −$49.3M |
| Net profit margin | 41.94% | 41.53% | 42.31% | 37.56% | 28.23% | — | −7.21% | 36.20% | 24.22% | 44.64% | 44.45% | — | — | — | — | 17.86% | 5.42% | −17.52% |
| Basic EPSper basic share | $30.13 | $26.44 | $21.04 | $15.98 | $10.60 | $11.65 | -$2.39 | $13.54 | $9.50 | $16.29 | $14.17 | $7.06 | $3.49 | $5.84 | $3.81 | $1.89 | $0.37 | -$1.08 |
| Diluted EPSper diluted share | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 | $11.54 | -$2.39 | $13.39 | $9.31 | $15.25 | $12.72 | $6.28 | $3.28 | $5.71 | $3.67 | $1.78 | $0.35 | -$1.08 |
Owners
Reported shareholders
12.41%of listed shares
BlackRock, Inc.5.29M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 12.41%5.29M shares |
Avoro Capital Advisors LLC | 6.51%2.78M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.50%1.92M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.49%1.92M shares |
STATE STREET CORP | 4.45%1.9M shares |
RENAISSANCE TECHNOLOGIES LLC | 4.00%1.71M shares |
WELLINGTON MANAGEMENT GROUP LLP | 3.23%1.38M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.34%996.6K shares |
Jupiter Topco LLC | 1.95%831.13K shares |
NORGES BANK | 1.63%694.75K shares |
ASSETMARK, INC | 1.46%624.07K shares |
AQR CAPITAL MANAGEMENT LLC | 1.28%546K shares |
DIMENSIONAL FUND ADVISORS LP | 1.24%527.9K shares |
FMR LLC | 1.11%473.41K shares |
Invesco Ltd. | 1.11%473.11K shares |
BAILLIE GIFFORD & CO | 1.09%467.21K shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 1.07%457K shares |
MORGAN STANLEY | 1.02%436.7K shares |
Vestal Point Capital, LP | 1.02%435K shares |
NORTHERN TRUST CORP | 1.01%430.84K shares |
Percentages use 42.68M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | ROTHBLATT MARTINE AChairperson & CEO | SellCommon Stock | 430 | $548.96 | $236.1K | 40.5K |
| Jun 29, 2026Form 4 · 10b5-1 | ROTHBLATT MARTINE AChairperson & CEO | SellCommon Stock | 1.7K | $548.29 | $933.2K | 40.9K |
| Jun 29, 2026Form 4 · 10b5-1 | ROTHBLATT MARTINE AChairperson & CEO | SellCommon Stock | 759 | $547.12 | $415.3K | 42.6K |
| Jun 29, 2026Form 4 · 10b5-1 | ROTHBLATT MARTINE AChairperson & CEO | SellCommon Stock | 1.7K | $546.28 | $931.4K | 43.4K |
| Jun 29, 2026Form 4 · 10b5-1 | ROTHBLATT MARTINE AChairperson & CEO | SellCommon Stock | 2.2K | $545.30 | $1.18M | 45.1K |